Michael R Loebinger

Dec 4, 2024 | resmedjournal.com | UCL Respiratory |Michael Tunney |Zina Alfahl |Gisli G Einarsson |J. Stuart Elborn |Deirdre F Gilpin | +10 more

KeywordsBronchiectasismicrobiome compositionquantitative real time PCRbacterial densityclinical outcomesquality of lifeGet full text accessLog in, subscribe or purchase for full access. REFERENCES1. O’Donnell, A.E.Bronchiectasis updateCurrent Opinion in Infectious Diseases. 2018; 312. Chandrasekaran, R. ∙ Mac Aogáin, M. ∙ Chalmers, J.D. ... Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasisBMC Pulmonary Medicine. 2018; 18:833. Chalmers, J.D. ∙ Polverino, E.

Oct 14, 2024 | dialnet.unirioja.es | Kartik Kumar |Michael R Loebinger

Ayuda Buscar en la ayuda Buscar en la ayuda Non-Tuberculous Mycobacterial Pulmonary Disease—Where are we Now? Kartik Kumar [1] ; Michael R.

Sep 1, 2024 | openres.ersjournals.com | Michael R Loebinger |Stefano Aliberti |Charles S. Haworth |Christoph Lange

FootnotesProvenance: Submitted article, peer reviewed. Authors contributions: M.R. Loebinger and J. van Ingen conceived and developed the surveys for all rounds of voting. All panellists and authors discussed and shaped the content for voting Rounds 2 and 3. All authors discussed the content of the manuscript from the face-to-face meetings; they also conceived and developed the outline and all manuscript drafts. All authors critically reviewed and approved the final draft for submission.

Jun 6, 2024 | erj.ersjournals.com | Stefano Aliberti |Eva Polverino |Charles S. Haworth |Michael R Loebinger

IntroductionImpaired mucociliary clearance is one of the defining features of the clinical syndrome of bronchiectasis [1, 2]. The most frequent symptoms that impact upon patients’ quality of life are cough and sputum production, commonly characterised by secretions with high viscoelasticity [3–5].

Apr 18, 2024 | erj.ersjournals.com | Stefano Aliberti |Felix C. Ringshausen |Charles S. Haworth |Michael R Loebinger

IntroductionBronchiectasis is a chronic inflammatory disease [1, 2]. Although it is recognised that bronchiectasis is composed of multiple phenotypes and endotypes, inflammation has classically been regarded as neutrophilic and patients with higher levels of neutrophilic inflammation have been shown to have worse clinical outcomes [3–5]. Although there are composite severity and prognostic assessment tools for bronchiectasis, there are currently no direct measures of inflammation [5–7].